PhRMA v. HHS
D.C. federal court will hear additional arguments on the Pharmaceutical Research & Manufacturers of America's challenge of HHS' approval of the Michigan Medicaid supplemental rebate program Jan. 24. The court wants information on the effect the non-Medicaid aspects of the program will have on Medicaid beneficiaries. During oral arguments Jan. 6, the Department of Justice said the court should defer to HHS' approval (1"The Pink Sheet" Sept. 2, p. 6)...
You may also be interested in...
HHS' approval of the Michigan Medicaid supplemental rebate program should be given deference in the Washington, D.C. federal court's review of the program, the Department of Justice said during oral arguments Aug. 28
Notified bodies’ efforts to enhance a harmonized approach to remote audits have failed, raising questions about whether there is any avenue left to get vital devices certified by the 26 May EU MDR deadline.
As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.